BEIJING, June 14, 2011 /PRNewswire-Asia-FirstCall/ — China
Medical Technologies, Inc. (the “Company”) (Nasdaq:
CMED), a leading China-based advanced in-vitro diagnostic
(“IVD”) company, today announced that Chengxuan, a major
shareholder which is owned by Mr. Xiaodong Wu, Chairman and Chief
Executive Officer of the Company, informed the Company that
Chengxuan purchased 110,000 of the Company’s American Depositary
Shares (“ADSs”) in the open market on June 13, 2011 at an average
price of US$7.33 per ADS. Chengxuan also indicated the
intention to purchase additional ADSs in the open market in the
future in compliance with the Company’s insider trading policy.
About China Medical Technologies, Inc.
China Medical Technologies, Inc. is a leading China-based
advanced IVD company using molecular diagnostic technologies
including Fluorescent in situ Hybridization (FISH) and Surface
Plasmon Resonance (SPR) and an immunodiagnostic technology,
Enhanced Chemiluminescence Immunoassay (ECLIA), to develop,
manufacture and distribute diagnostic products used for the
detection of various cancers, diseases and disorders as well as
companion diagnostic tests for targeted cancer drugs. The Company
generates all of its revenues in China through the sale of
diagnostic consumables including FISH probes, SPR-based DNA chips
and ECLIA reagent kits to hospitals which are recurring users of
the consumables for their patients. The Company sells FISH probes
and SPR chips to large hospitals through its direct sales personnel
and ECLIA reagent kits to small and mid-size hospitals through
distributors. For more information, please visit http://www.chinameditech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements constitute “forward-looking” statements within the
meaning of Se
‘/>”/>
